Earnings Call · Q3 FY2024·2024-11-08

Q3 24EPS +36.30%·Rev n/aQ2 24EPS +32.08%·Rev n/aQ1 24EPS +44.58%·Rev n/aQ4 23EPS +100.00%*·Rev n/a⚠ consensus missing

LIGAND PHARMACEUTICALS INC LGND

Melanie Herman — Investor Relations or Communications Officer

Todd Davis — Chief Executive Officer

Karen Reeves — Commercial/Business Development Executive

Tavo Espinoza — Chief Financial Officer or Finance Executive

+11.1%1d on move date+10.3% vs SPY3d+5.6%5d+4.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LGND calls or request research access.

More LGND calls Browse calls Request research access